California scientist recognized by American Heart Association for innovative trials improving care of heart disease patients with blood-clot complications
Embargoed until 5 a.m. PT/8 a.m. ET, Monday, Nov. 13, 2017
ANAHEIM, California, Nov. 13 -- The American Heart Association awarded its Clinical Research Prize for 2017 to Robert A. Harrington., M.D., of Stanford University School of Medicine, “for his leadership of research initiatives leading to the development of new anti-thrombotic agents that have dramatically improved everyday medical practice.”
Harrington received the prize during Sunday’s opening ceremony of the AHA Scientific Sessions 2017, a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians, which was held at the Anaheim Convention Center. Association President John Warner, M.D., of the University of Texas Southwestern Medical Center at Dallas presented the prize, a citation and $5,000 honorarium, awarded annually for outstanding achievement in clinical cardiovascular science.
In presenting the prize, Warner lauded the California interventional cardiologist “for his creative development of novel approaches to the design and conduct of clinical trials focused on improving care of patients with coronary artery disease and its complications.”
Harrington is considered one of the most innovative investigators applying effective new approaches to the design and conduct of clinical trials.
“He has focused his investigative efforts on improving the care of coronary heart disease patients with blood-clotting complications, through a series of landmark studies that have become pivotal to gaining regulatory approval of anti-thrombotic medications across multiple indications,” Warner said.
“Dr. Harrington played a critical role in guiding the clinical development of these new programs, which have substantially increased our understanding of the use of a number of agents that are now part of routine medical practice.”
The prize winner is chairman of the Department of Medicine and the Arthur L. Bloomfield Professor of Medicine at Stanford University in Stanford, California.
For more news at AHA Scientific Sessions 2017, follow us on Twitter @HeartNews #AHA17.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
For Media Inquiries and AHA Spokesperson Perspective:
AHA News Media in Dallas: 214-706-1173
AHA News Media Office, Nov. 11-15, 2017 at the Anaheim Convention Center: 714-765-2004
For Public Inquiries: 800-AHA-USA1 (242-8721)